Tag: NOVEL

  • 78c

    Thiazoloquin(az)olin(on)e small-molecule CD38 NADase inhibitor

    A potent, specific, reversible, and uncompetitive small-molecule inhibitor of the NAD+ glycohydrolase CD38, developed from a thiazoloquinolin(on)e medicinal chemistry series and distinguished by low-nanomolar potency, oral bioavailability, and demonstrated reversal of age-related tissue NAD+ decline with extension of lifespan and healthspan in murine aging models.

    Abstract

    Compound 78c (CD38-IN-78c; CAS 1700637-55-3) is a thiazoloquinolin(on)e small molecule identified as the lead compound from a structure-activity exploration of CD38 inhibitors reported by Haffner, Bhatt, and colleagues in 2015. It is a potent, specific, reversible, and uncompetitive inhibitor of the ectoenzyme CD38 (cluster of differentiation 38), a type II transmembrane glycoprotein with NAD+ glycohydrolase, ADP-ribosyl cyclase, and cyclic ADP-ribose hydrolase activities, with half-maximal inhibitory concentration (IC50) values of 7.3 nM against human CD38 and 1.9 nM against murine CD38, and an inhibition constant (Ki) of 8.4 nM. The compound is cell-permeable, orally bioavailable in rodent species, and non-toxic at pharmacologically active doses in chronic administration studies extending to 20 months. CD38 has been identified as the principal enzyme responsible for age-related tissue NAD+ decline, a process that contributes to mitochondrial dysfunction, impaired sirtuin signaling, metabolic derangement, and the progressive physiological deterioration characteristic of aging. By inhibiting CD38-mediated degradation of NAD+ and its biosynthetic precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), compound 78c elevates tissue NAD+ levels (greater than 5-fold in liver and greater than 1.2-fold in skeletal muscle in diet-induced obese mice at a 2-hour time point) and thereby restores the activity of NAD+-dependent enzymes including sirtuins 1, 3, and 6 and poly(ADP-ribose) polymerases.

    The landmark 2018 publication by Tarrago, Chini, and colleagues in Cell Metabolism demonstrated that chronic oral administration of 78c to naturally aged mice and to Cockayne syndrome progeroid mice reverses age-related NAD+ decline and improves glucose tolerance, exercise capacity, muscle function, and cardiac function. A follow-up 2022 study by Peclat and colleagues in Aging Cell extended these findings to chronological aging, reporting that 78c increases median lifespan by approximately 10 percent, extends maximal lifespan, and improves multiple healthspan parameters including treadmill endurance, grip strength, body composition, and metabolic markers in naturally aged C57BL/6 mice, with sex-dependent differences in the magnitude of benefit. Additional preclinical studies have demonstrated cardioprotection against ischemia-reperfusion injury through preservation of tetrahydrobiopterin (BH4) and endothelial nitric oxide synthase coupling; anti-inflammatory activity through suppression of NF-kappaB-dependent cytokine expression (IL-1beta, IL-6, TNF-alpha) in macrophages and microglia; therapeutic efficacy in collagen-induced arthritis through restoration of regulatory T cell populations and immune balance; and attenuation of osteoclastogenesis and inflammatory bone resorption. The compound does not cross the blood-brain barrier at appreciable concentrations but exerts systemic anti-inflammatory and metabolic effects relevant to age-related neurodegeneration through peripheral NAD+ homeostasis.

    Compound 78c has not entered human clinical trials. It is supplied by multiple research chemical vendors at greater than 98 percent purity as a research tool compound. The current research state is one of strong and replicable preclinical efficacy across aging, cardiovascular, inflammatory, and metabolic disease models, with absent clinical pharmacokinetic and safety data in humans. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cogitum

    Acetylated amino acid derivative; synthetic N-acetylaspartate analog with neurometabolic and adaptogenic activity

    A potassium salt of N-acetyl-DL-aminosuccinic acid developed in France as an oral neurometabolic tonic for asthenic syndrome, cognitive fatigue, and pediatric neurodevelopmental delay, distinguished by its structural relationship to endogenous N-acetylaspartate and downstream modulation of glutamatergic and myelinogenic pathways.

    Abstract

    Cogitum is the proprietary pharmaceutical preparation of potassium N-acetyl-DL-aminosuccinate (bipotassium acetylaminosuccinate), a synthetic analog of N-acetylaspartate (NAA), the most concentrated free amino acid derivative in the mammalian central nervous system. The compound was developed in France and patented in the United States in 1969 (US 3,433,875) for the improvement of mental performance in adults experiencing intellectual overwork, memory disorders, and cognitive decline associated with senescence. The active substance provides an exogenous source of the acetylated aspartate moiety that participates in neuronal energy metabolism through the tricarboxylic acid cycle, serves as the obligate precursor for myelin lipid synthesis via oligodendrocytic aspartoacylase-mediated deacetylation, functions as an osmolyte maintaining neuronal volume homeostasis, and is the direct biosynthetic precursor of N-acetylaspartylglutamate (NAAG), the most abundant neuropeptide in the human brain and an endogenous agonist at the presynaptic metabotropic glutamate receptor type 3 (mGluR3).

    Pediatric evidence comprises a 249-patient study in children with ADHD and subclinical epileptiform electroencephalographic activity demonstrating significant improvements in attention, memory, and speech without aggravation of epileptiform discharges or provocation of seizures; additional cohort studies in children with speech delay, traumatic brain injury sequelae, mental retardation, and schizotypal spectrum disorders have reported efficacy in improving cognitive and linguistic performance. The pharmacological rationale rests on the established neurobiology of endogenous N-acetylaspartate: NAA concentrations in the brain reach 10 millimolar or greater, are confined almost exclusively to neurons, and serve as the principal magnetic resonance spectroscopy marker of neuronal viability; reduced NAA is a consistent finding in neurodegenerative disease, traumatic brain injury, multiple sclerosis, and neurodevelopmental disorders. The exogenous provision of the acetylaminosuccinate moiety is hypothesized to support neuronal mitochondrial energy production, to provide acetate substrate for oligodendrocytic myelin lipid synthesis, and to augment NAAG-mediated glutamatergic neuromodulation.

    Safety data across pediatric and adult populations demonstrate excellent tolerability. The compound has no reported cases of overdose toxicity, produces no clinically significant drug interactions at registered doses, and is contraindicated only in cases of known hypersensitivity to the active substance or excipients. The principal limitation of the evidence base is the concentration of clinical research in Russian-language journals with limited replication in Western multicenter trial frameworks. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • AAZ-A-154

    Non-hallucinogenic psychoplastogen; isotryptamine-derived 5-HT2A receptor partial agonist with neuroplasticity-promoting activity

    A non-hallucinogenic isotryptamine psychoplastogen discovered via engineered 5-HT2A biosensor screening at UC Davis, producing rapid and sustained antidepressant-like effects through serotonin receptor-mediated structural neuroplasticity without psychedelic, dissociative, or psychotomimetic activity.

    Abstract

    AAZ-A-154, subsequently designated DLX-001 and assigned the international nonproprietary name zalsupindole, is a substituted isotryptamine derivative that acts as a low-potency, low-efficacy partial agonist of the serotonin 5-HT2A receptor (EC50 approximately 8,200 nM; Emax approximately 17 percent of serotonin maximum) and a moderate-efficacy partial agonist of the 5-HT2C receptor (EC50 approximately 3,300 nM; Emax approximately 70 percent), with silent antagonism at the 5-HT2B receptor and selectivity for serotonergic over dopaminergic, adrenergic, and opioid targets. The compound was first synthesized in 2019 in the laboratory of David E. Olson at the University of California, Davis, and was identified from a library screen using psychLight, a genetically encoded fluorescent biosensor constructed from the human 5-HT2A receptor with a circularly permuted green fluorescent protein inserted into the third intracellular loop [1]. PsychLight discriminated hallucinogenic from non-hallucinogenic 5-HT2A ligands on the basis of differential conformational activation signatures, and AAZ-A-154 was selected as a lead compound on the basis of its favorable ligand score, a metric that predicted non-hallucinogenic character despite retention of 5-HT2A-dependent psychoplastogenic activity.

    The compound is structurally related to 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) but is an isotryptamine (the aminoalkyl side chain is attached to the indole nitrogen at position 1 rather than at position 3), a modification that repositions the compound in chemical space outside classical psychedelic tryptamines. The (R)-enantiomer is the active form; the alpha-methyl substituent on the aminoalkyl chain confers metabolic stability and enantioselective receptor engagement. The compound increased dendritic arbor complexity in cultured embryonic rat cortical neurons to a degree comparable to ketamine, and the neuroplastogenic effect was abolished by the 5-HT2 receptor antagonist ketanserin, confirming receptor dependence [1].

    A comprehensive preclinical characterization published by Agrawal et al. (2025) in ACS Chemical Neuroscience demonstrated that zalsupindole promoted cortical neuritogenesis in vitro, increased dendritic spine density in the prefrontal cortex in vivo, and enhanced measures of functional plasticity to a degree comparable to or greater than ketamine, psilocybin, and N,N-dimethyltryptamine, despite lacking any of the acute cellular and behavioral characteristics of hallucinogenic or dissociative compounds [2]. Pharmacokinetic studies revealed high brain penetrance, rapid distribution, and rapid clearance. A Phase 1b study in 18 adults with major depressive disorder reported clinically meaningful reductions in Montgomery-Asberg Depression Rating Scale scores of approximately 12 points (approximately 50 percent improvement) by Day 8, with effects maintained through Day 36, and comparable efficacy between a seven-day once-daily regimen and a two-dose regimen [5]. No serious adverse events were reported across more than 120 individuals studied. Dose-dependent nausea, headache, and dizziness were the principal mild adverse events. In October 2025, the United States Food and Drug Administration cleared the Investigational New Drug application for a Phase 2, multi-site, randomized, double-blind, placebo-controlled trial in major depressive disorder featuring at-home self-administration [5]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • CT1812

    Selective sigma-2 receptor (TMEM97) complex antagonist with anti-amyloid-beta oligomer synaptoproctective activity

    A first-in-class, orally bioavailable isoindoline sigma-2 receptor antagonist developed by Cognition Therapeutics to displace amyloid-beta oligomers from neuronal synapses, with Phase 2 clinical evidence of cognitive benefit in Alzheimer’s disease and dementia with Lewy bodies.

    Abstract

    CT1812 (zervimesine; CAS 1802632-22-9) is a first-in-class, orally bioavailable small-molecule antagonist of the sigma-2 receptor complex (also designated TMEM97, transmembrane protein 97) developed by Cognition Therapeutics for the treatment of Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and geographic atrophy secondary to dry age-related macular degeneration. The compound was identified through a phenotypic neuronal screening assay designed to detect reversal of amyloid-beta oligomer (ABO) induced synaptotoxicity and was chemically optimized from a series of isoindoline scaffolds selected for central nervous system penetration, metabolic stability, and selectivity against cardiac ion channel (hERG) liability. CT1812 binds the sigma-2 receptor with a Ki of 8.5 nM and demonstrates greater than 100-fold selectivity over a broad receptor panel, with approximately 10-fold selectivity over the sigma-1 receptor. The mechanism of action is allosteric antagonism of the sigma-2 receptor complex, which includes TMEM97, progesterone receptor membrane component 1 (PGRMC1), and low-density lipoprotein receptor (LDLR) at the neuronal surface. Engagement of this complex by CT1812 induces a conformational change that displaces prebound amyloid-beta oligomers from synaptic receptors without affecting oligomer assembly or dissociation, thereby restoring synaptic trafficking, reducing synaptotoxicity, and facilitating clearance of oligomers into the cerebrospinal fluid.

    In preclinical studies, CT1812 demonstrated robust brain penetration (brain-to-plasma ratio of 5.7 at 24 hours; unbound brain-to-plasma partition coefficient Kp,uu of 6.75), achieved greater than 84 percent sigma-2 receptor occupancy at therapeutically relevant doses, and improved cognitive performance in transgenic Alzheimer’s mouse models across Y-maze, Morris water maze, and fear conditioning paradigms. The compound is not a P-glycoprotein substrate, exhibits favorable oral absorption with time to peak plasma concentration of 1 to 2 hours and a plasma elimination half-life of approximately 12 hours in humans, and is metabolized primarily by CYP3A4 with secondary contributions from CYP2D6 and CYP2C19.

    A Phase 1b/2 trial (COG0102) in 19 patients with mild to moderate AD demonstrated reductions in cerebrospinal fluid synaptic damage markers (neurogranin and synaptotagmin-1) and decreases of 30 percent or more in six tau phosphorylation sites after 28 days of treatment. The Phase 2 SHIMMER trial (COG1201) enrolled 130 patients with mild to moderate DLB and met its primary safety endpoint; secondary analyses showed 82 percent of treated patients demonstrated slowing on the total Neuropsychiatric Inventory, with a 91 percent reduction in decline of attentional fluctuation measures. CT1812 has also been evaluated in the Phase 2 MAGNIFY trial for geographic atrophy, where treated patients showed 28.6 percent slower lesion growth over 18 months compared to placebo. CT1812 is positioned for Phase 3 development in Alzheimer’s disease. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cytoflavin

    Fixed-dose combination metabolic cytoprotectant comprising succinic acid, inosine, nicotinamide, and riboflavin for mitochondrial energy rescue and antihypoxant neuroprotection

    A four-component metabolic combination drug developed by POLYSAN Ltd. that supplies Krebs cycle substrate, purine nucleoside, NAD+ precursor, and FAD cofactor to restore aerobic energy production in ischemic, hypoxic, and neurodegenerative tissue.

    Abstract

    Cytoflavin is a fixed-dose combination metabolic agent comprising succinic acid (the principal mass component and Krebs cycle substrate), inosine (a purine nucleoside and precursor to adenine nucleotides), nicotinamide (the amide form of vitamin B3 and precursor to nicotinamide adenine dinucleotide), and riboflavin (vitamin B2, the precursor to flavin adenine dinucleotide and flavin mononucleotide). The pharmacological rationale is the simultaneous provision of four complementary metabolic substrates and cofactors whose intracellular availability becomes rate-limiting during ischemia, hypoxia, and oxidative stress: succinic acid feeds directly into mitochondrial Complex II (succinate dehydrogenase), bypassing the NAD-dependent steps of the Krebs cycle that fail under hypoxic conditions; inosine supports purine salvage and ATP resynthesis; nicotinamide replenishes the NAD+ pool consumed by poly(ADP-ribose) polymerase activation during ischemic injury; and riboflavin provides the FAD prosthetic group required for succinate dehydrogenase function and for multiple flavoprotein-dependent antioxidant enzymes including glutathione reductase.

    The clinical evidence base for Cytoflavin spans ischemic stroke (acute and chronic cerebral ischemia), traumatic brain injury, diabetic polyneuropathy, postoperative cognitive decline in elderly surgical patients, post-COVID-19 asthenic syndrome, and organic asthenic disorder. The largest and most rigorous published trial is the CYLINDER study, a multicenter, double-blind, placebo-controlled, randomized trial in 216 patients with type 2 diabetes mellitus and symptomatic distal sensorimotor diabetic polyneuropathy conducted across 10 Russian clinical centers, which reported a statistically significant reduction in Total Symptom Score (TSS change of negative 2.65 points in the experimental group versus negative 1.73 points in the placebo group, p less than 0.001) after a sequential intravenous-then-oral treatment regimen. In acute ischemic stroke, multicenter studies have demonstrated marked reduction in neurological deficit severity by day 10 and higher probability of favorable functional outcome compared to standard-of-care controls. The CITADEL prospective randomized study demonstrated a pronounced anti-asthenic effect and correction of cognitive impairments in post-COVID-19 rehabilitation. An international, multicenter, randomized, single-blind, placebo-controlled trial (NCT04631484) evaluating Cytoflavin in moderate traumatic brain injury in adults was completed in 2024, with results published in Frontiers in Neurology in 2025, representing the first large-scale international trial of the compound outside the Russian Federation and Commonwealth of Independent States.

    Cytoflavin is registered as a medicinal product in the Russian Federation and in Vietnam. The manufacturing facility holds GMP EU certification. The compound is not approved by the United States Food and Drug Administration, by the European Medicines Agency, or by other major Western regulatory authorities. The clinical literature is predominantly in Russian-language journals, with an expanding body of English-language publications in international peer-reviewed venues. The safety profile across published clinical studies is favorable; the principal adverse events are transient epigastric discomfort, headache, hyperuricemia (attributable to inosine-derived purine catabolism), and rare hypersensitivity reactions. No serious adverse events attributable to the drug have been reported in published controlled trials.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Procyanidin C1

    B-type proanthocyanidin trimer (oligomeric flavan-3-ol) with senolytic, senomorphic, and multi-target anti-inflammatory activity

    A naturally occurring epicatechin trimer from grape seed extract identified as a dual-mode senotherapeutic agent that selectively eliminates senescent cells at high concentrations while suppressing the senescence-associated secretory phenotype at low concentrations, with demonstrated lifespan extension in mice and emerging preclinical evidence across fibrotic, neurodegenerative, and oncologic indications.

    Abstract

    Procyanidin C1 (PCC1) is a B-type proanthocyanidin trimer composed of three (2R,3R)-(-)-epicatechin units joined by two successive (4beta to 8)-interflavan bonds, with molecular formula C45H38O18 and molecular weight 866.77 g/mol. The compound is a polyphenolic constituent of grape seed extract (GSE), cocoa, cinnamon bark, unripe apple peel, and pine bark, and was first structurally characterized in the 1980s as part of the broader oligomeric proanthocyanidin (OPC) family originally described by Masquelier in 1947. PCC1 remained a minor analytical curiosity within the proanthocyanidin literature until 2021, when a landmark screening study by Xu, Fu, and colleagues, published in Nature Metabolism, identified PCC1 as a potent and selective senotherapeutic agent capable of extending healthspan and lifespan in aged mice through dual-mode activity on senescent cells [1]. At low concentrations (below approximately 50 micromolar), PCC1 acts as a senomorphic agent, suppressing the production of pro-inflammatory senescence-associated secretory phenotype (SASP) factors through inhibition of NF-kappaB signaling without inducing senescent cell death. At higher concentrations (above approximately 100 micromolar), PCC1 transitions to a senolytic mode, selectively inducing apoptosis in senescent cells through a reactive oxygen species (ROS)-dependent mitochondrial dysfunction pathway involving the p53-Puma/Noxa axis, while sparing proliferating and quiescent non-senescent cells. This concentration-dependent functional switch distinguishes PCC1 from most other characterized senolytic agents and provides a pharmacological basis for dose-titrated senotherapeutic intervention.

    Subsequent preclinical studies have expanded the evidence base substantially. Zhu, Huang, and colleagues (2024) demonstrated that PCC1 alleviates structural and functional decline in the aged mouse retina through combined senolytic and senomorphic mechanisms [2]. Gan and colleagues (2025) reported that PCC1 alleviates renal fibrosis by promoting apoptosis of senescent renal tubular epithelial cells [3]. Additional preclinical evidence supports activity against skin fibrosis through EGFR inhibition and TGF-beta/SMAD pathway suppression [4], neuroprotection through Nrf2/HO-1 signaling activation [5], endothelial nitric oxide production through PI3K/Akt-dependent eNOS phosphorylation [6], insulin sensitization in adipocytes through AKT-eNOS pathway activation [7], and colon cancer growth inhibition through miR-501-3p/HIGD1A axis modulation [8]. Single-cell profiling has revealed broad geroprotective effects on the hematopoietic immune system, including restoration of B cell and hematopoietic stem cell populations and suppression of senescence-associated inflammatory markers [9].

    Pharmacokinetically, PCC1 shares the absorption limitations characteristic of oligomeric proanthocyanidins: oral bioavailability of trimeric procyanidins is low, with the majority of ingested material reaching the colon intact where it is degraded by gut microbiota into phenylvalerolactones, phenylvaleric acids, and smaller phenolic acid metabolites. Phytosomal formulations have demonstrated 2- to 3-fold improvements in gastrointestinal absorption efficiency. No completed Phase 1 or Phase 2 clinical trials of purified PCC1 have been published as of the most recent monograph revision, though preliminary findings from phytosomal PCC1 formulations have shown reductions in senescence markers in peripheral blood mononuclear cells from elderly individuals. The compound is not approved by any regulatory authority for therapeutic use. It is available as a research-grade preparation from multiple chemical suppliers at greater than 95 percent purity by HPLC. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Apelin-13

    Endogenous bioactive peptide agonist of the apelin receptor (APJ/APLNR), a class A G protein-coupled receptor

    A pyroglutamyl-modified tridecapeptide derived from the C-terminus of preproapelin, identified as the predominant circulating isoform and the highest-potency endogenous agonist of the APJ receptor, with characterized cardiovascular inotropic, vasodilatory, aquaretic, metabolic, and neuroprotective activities.

    Abstract

    Apelin-13, the C-terminal tridecapeptide fragment of the 77-amino-acid preproapelin precursor, is the most potent endogenous agonist of the apelin receptor (APJ, also designated APLNR), a class A rhodopsin-like G protein-coupled receptor originally cloned as an orphan receptor in 1993 by O’Dowd et al. on the basis of sequence homology with the angiotensin II type 1 receptor. The receptor was deorphanized in 1998 by Tatemoto and colleagues at the Takeda Chemical Research Institute, who isolated apelin from bovine stomach extracts using an extracellular acidification assay on APJ-expressing Chinese hamster ovary cells and demonstrated that apelin-13 displayed 8- to 60-fold higher potency than the longer apelin-36 isoform. The predominant circulating form in human plasma is [Pyr1]apelin-13 (pyroglutamyl apelin-13), in which the N-terminal glutamine residue undergoes spontaneous or enzymatic cyclization to pyroglutamate, conferring modest resistance to aminopeptidase degradation and representing the principal bioactive isoform in cardiovascular tissue and plasma.

    Apelin-13 activates APJ with sub-nanomolar potency (EC50 approximately 0.37 nM in cellular acidification assays), coupling predominantly through Gi/o proteins to inhibit adenylyl cyclase and reduce intracellular cAMP, through Gq/11 to activate phospholipase C and mobilize intracellular calcium, and through G12/13 to engage RhoA-dependent cytoskeletal rearrangement. The receptor also recruits beta-arrestin 1 and 2, mediating receptor internalization and activating extracellular signal-regulated kinase 1/2 (ERK1/2) through G protein-independent pathways. The downstream signaling cascade includes activation of phosphoinositide 3-kinase (PI3K)/Akt, endothelial nitric oxide synthase (eNOS), AMP-activated protein kinase (AMPK), and inhibition of reactive oxygen species generation, collectively producing the cardiovascular, metabolic, and cytoprotective effects that define the pharmacological profile.

    The cardiovascular pharmacology of apelin-13 is the most extensively characterized domain. In human clinical studies, systemic infusion of [Pyr1]apelin-13 at 30 to 300 nmol/min produces a sustained approximately 10 percent increase in cardiac index, increased ejection fraction, reduced systemic vascular resistance by approximately 12 percent, and reduced mean arterial pressure by approximately 4 percent, effects observed in both healthy volunteers and patients with chronic heart failure and chronic kidney disease. The mechanism involves direct positive inotropic action on cardiomyocytes through APJ-mediated calcium sensitization, nitric oxide-dependent vasodilation in resistance arteries, and counter-regulatory opposition to the renin-angiotensin-aldosterone system. Preclinical models demonstrate cardioprotective effects in myocardial infarction, ischemia-reperfusion injury, pressure-overload hypertrophy, and diabetic cardiomyopathy, with mechanisms including salvage of the peri-infarct border zone, mobilization of endogenous cardiac stem cells, and suppression of pathological fibrosis.

    The renal pharmacology is defined by the functional antagonism between apelin and arginine vasopressin (AVP) at the collecting duct. Apelin-13 inhibits vasopressin-induced translocation of aquaporin 2 (AQP2) water channels to the apical membrane of principal cells through Gi-mediated inhibition of cAMP/protein kinase A signaling, producing a diuretic (aquaretic) effect that opposes AVP-driven water reabsorption. This reciprocal regulation positions the apelin/AVP axis as a physiological rheostat for water homeostasis, with therapeutic implications for hyponatremia and states of AVP excess.

    Metabolic pharmacology encompasses insulin-sensitizing and glucoregulatory effects. Apelin-13 administration in diabetic rodent models reduces blood glucose, increases serum insulin, improves pancreatic islet mass, and enhances glucose uptake in skeletal muscle through AMPK-dependent GLUT4 translocation. Neuroprotective activity has been demonstrated in models of ischemic stroke, diabetes-associated cognitive decline, and excitotoxic injury, with mechanisms including antioxidant defense through the SIRT3/FoxO3 pathway, anti-inflammatory cytokine modulation, and direct neuronal survival signaling through PI3K/Akt.

    The principal pharmacokinetic limitation of apelin-13 is its extremely short plasma half-life. Native [Pyr1]apelin-13 has a plasma half-life of approximately 21 to 24 minutes in rodents, driven by rapid proteolytic degradation at the Leu5-Ser6 peptide bond by neprilysin, angiotensin-converting enzyme 2 (ACE2), and plasma kallikrein. This has motivated extensive medicinal chemistry efforts to develop stabilized analogues (macrocyclic peptides, D-amino acid substitutions, PEGylation) and small-molecule APJ agonists (AMG-986, BMS-986224, azelaprag) for chronic administration.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Aticaprant

    Selective kappa-opioid receptor (KOR) antagonist with short-acting, non-inactivating pharmacodynamic profile

    A potent, orally bioavailable aminobenzyloxyarylamide kappa-opioid receptor antagonist developed at Eli Lilly and advanced through Phase 3 clinical evaluation for adjunctive treatment of major depressive disorder with anhedonia, distinguished from earlier KOR antagonists by favorable drug-like properties, short-acting receptor blockade, and a well-characterized safety profile.

    Abstract

    Aticaprant (LY-2456302, CERC-501, JNJ-67953964) is a potent, selective, orally bioavailable antagonist of the kappa-opioid receptor (KOR) with a binding affinity (Ki) of 0.81 nM, approximately 30-fold selectivity over the mu-opioid receptor (Ki = 24.0 nM), and approximately 190-fold selectivity over the delta-opioid receptor (Ki = 155 nM). The compound belongs to the aminobenzyloxyarylamide chemical class and was designed at Eli Lilly Research Laboratories as a clinically viable therapeutic targeting the endogenous dynorphin/KOR neuromodulatory system, a pathway implicated in the pathophysiology of stress-induced anhedonia, dysphoria, and addictive behaviors. In contrast to earlier KOR antagonists such as JDTic and nor-binaltorphimine, which exhibit ultra-long-duration receptor inactivation persisting for weeks after a single dose, aticaprant produces short-acting, reversible KOR blockade with an elimination half-life of 30 to 40 hours, enabling conventional once-daily oral dosing and predictable pharmacokinetic management.

    In rodent behavioral models, aticaprant produced antidepressant-like effects in the mouse forced swim test, enhanced the efficacy of imipramine and citalopram, reduced ethanol self-administration in alcohol-preferring (P) rats, and reversed unpredictable chronic mild stress-induced anhedonia in C57BL/6J mice, as measured by sucrose preference, nest building, and forced swim endpoints.

    Clinical development of aticaprant has proceeded through multiple sponsors. Eli Lilly conducted the initial Phase 1 single- and multiple-ascending dose studies (Lowe et al. 2014), establishing safety, tolerability, and the absence of clinically significant interactions with ethanol. Cerecor Inc. acquired the compound in 2015 and initiated early clinical studies in mood and substance use disorders. Janssen Pharmaceuticals (Johnson and Johnson) acquired the compound in 2017 and advanced it through Phase 2 and Phase 3 programs for adjunctive treatment of major depressive disorder (MDD) in patients with inadequate response to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). The Phase 2 randomized, double-blind, placebo-controlled study (Jacobsen et al. 2024) in 181 participants with MDD and moderate-to-severe anhedonia demonstrated a statistically significant reduction of 2.1 points on the Montgomery-Asberg Depression Rating Scale (MADRS) for aticaprant 10 mg versus placebo (p = 0.04), with favorable tolerability and no new safety signals. However, the compound did not separate from placebo on secondary measures of anhedonia (Snaith-Hamilton Pleasure Scale), global illness severity (CGI-S), anxiety (HAM-A), or patient-reported depression outcomes.

    Janssen subsequently initiated the VENTURA Phase 3 program comprising five pivotal trials in MDD with anhedonia. On 6 March 2025, Johnson and Johnson announced discontinuation of the VENTURA program due to insufficient efficacy in the target population, while noting that the compound remained safe and well tolerated with no new safety signals detected. The most common treatment-emergent adverse events in clinical trials were headache (11.8% versus 7.1% placebo), diarrhea (8.2% versus 2.4%), nasopharyngitis (5.9% versus 2.4%), and pruritus (5.9% versus 0%). Johnson and Johnson has indicated that it will explore future development opportunities for aticaprant in other areas of high unmet need. The compound is not approved by any regulatory authority for any indication. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • ISRIB

    Small-molecule eIF2B activator and integrated stress response inhibitor

    A symmetrical bis-glycolamide that stabilizes the decameric eIF2B holoenzyme, counteracting phospho-eIF2alpha-mediated translational repression and reversing age-related, traumatic, and neurodegenerative cognitive deficits in preclinical models without the pancreatic toxicity of upstream PERK kinase inhibitors.

    Abstract

    ISRIB (integrated stress response inhibitor) is a cell-permeable, brain-penetrant small molecule identified by Sidrauski et al. (2013) at the University of California, San Francisco, through a phenotypic screen for compounds that render cells resistant to the translational consequences of eukaryotic initiation factor 2 alpha (eIF2alpha) phosphorylation [1]. The compound blocks the integrated stress response (ISR) with an IC50 of approximately 5 nM in ATF4 reporter assays, operating downstream of all four eIF2alpha kinases (PERK, GCN2, HRI, PKR) at the level of the guanine nucleotide exchange factor eIF2B [2]. Cryo-electron microscopy studies (Tsai et al. 2018; Zyryanova et al. 2021) demonstrated that ISRIB binds at the symmetry interface of two eIF2B betagammadeltaepsilon tetrameric subcomplexes, acting as a molecular staple that promotes assembly of the catalytically active decameric holoenzyme and allosterically antagonizes the inhibitory effect of phosphorylated eIF2alpha on the nucleotide exchange reaction [3, 4]. The resulting restoration of ternary complex formation and global protein synthesis rates is partial rather than complete, reaching approximately 50 to 70 percent of unstressed control levels even at saturating compound concentrations, a feature that accounts for the favorable safety profile relative to direct PERK kinase inhibitors such as GSK2606414 that produce pancreatic exocrine destruction [5].

    Preclinical pharmacology spans multiple disease-relevant models. In cognition, ISRIB enhances spatial and fear-associated learning in wild-type mice (Sidrauski et al. 2013) [1], reverses cognitive deficits weeks after traumatic brain injury (Chou et al. 2017) [6], restores age-related memory decline and hippocampal neuronal function within days of treatment in aged mice (Krukowski et al. 2020) [7], and rescues synaptic plasticity in a mouse model of Down syndrome [8]. In neurodegeneration, ISRIB prevents neuronal loss in prion-diseased mice without pancreatic toxicity (Halliday et al. 2015) [5] and stabilizes vanishing white matter disease eIF2B mutant complexes to wild-type catalytic activity (Wong et al. 2018) [9]. Additional preclinical activity has been reported in prostate cancer [10], noise-induced cochlear synaptopathy [11], postinfarct atrial fibrillation [12], and amyotrophic lateral sclerosis models [13].

    No human clinical trials of ISRIB itself have been conducted. However, the compound served as the pharmacological prototype for two clinical-stage eIF2B activators: DNL343 (Denali Therapeutics), which completed a Phase 2/3 trial in amyotrophic lateral sclerosis (HEALEY platform trial) without meeting primary endpoints [14], and fosigotifator (Calico/AbbVie), which also failed to demonstrate significant slowing of disease progression in the same platform trial, although an exploratory high-dose arm showed signals on muscle strength preservation [15]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • BPAP

    Tryptamine-derived synthetic monoaminergic activity enhancer (MAE) with catecholaminergic and serotonergic impulse-propagation-mediated release enhancement and TAAR1 agonism

    A benzofuran-containing synthetic enhancer substance developed by Knoll and colleagues as the most potent known monoaminergic activity enhancer, selectively amplifying impulse-dependent release of dopamine, norepinephrine, and serotonin in the brain without monoamine oxidase inhibition or amphetamine-like releasing activity.

    Abstract

    (-)1-(Benzofuran-2-yl)-2-propylaminopentane, designated (-)BPAP and also known by the developmental code FPFS-1169, is a synthetic monoaminergic activity enhancer (MAE) structurally derived from phenylpropylaminopentane (PPAP) through replacement of the phenyl ring with a benzofuran heterocycle. First described by Jozsef Knoll and colleagues in 1999, BPAP represents the most potent synthetic enhancer substance characterized to date, approximately 130-fold more potent than selegiline ((-)-deprenyl) in antagonizing tetrabenazine-induced performance inhibition in the rat shuttle box paradigm, and is the first enhancer substance to augment serotonergic neurotransmission in addition to the catecholaminergic enhancement shared with selegiline and PPAP. The compound selectively amplifies the quantity of dopamine, norepinephrine, and serotonin released per nerve impulse from monoaminergic neurons without inducing spontaneous (impulse-independent) neurotransmitter release, a pharmacological property that distinguishes it fundamentally from amphetamine-type releasing agents and from monoamine oxidase inhibitors. The mechanism of the enhancer effect has been attributed, on the basis of pharmacological antagonism studies using the selective antagonist EPPTB, to agonism at trace amine-associated receptor 1 (TAAR1), which triggers PKC-dependent phosphorylation of SNARE complex proteins and vesicular monoamine transporter 2 (VMAT2), thereby increasing vesicular monoamine accumulation and exocytotic release. At substantially higher concentrations, BPAP also inhibits monoamine reuptake (predominantly dopamine and norepinephrine), though this activity is not considered pharmacologically relevant at the low nanogram-per-milliliter concentrations that produce the enhancer effect. In preclinical pharmacology, BPAP has demonstrated neuroprotective activity against N-methyl(R)salsolinol-induced apoptosis in human dopaminergic SH-SY5Y neuroblastoma cells through stabilization of mitochondrial membrane potential and upregulation of anti-apoptotic Bcl-2 protein expression. The compound upregulates synthesis and secretion of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) in cultured mouse astrocytes, with NGF secretion increased up to 120-fold over control at optimal concentrations. Pharmacokinetic characterization in rats indicates oral bioavailability with peak plasma levels at 30 to 60 minutes, a secondary peak at approximately 4 hours consistent with enterohepatic recirculation, a terminal elimination half-life of 5.5 to 5.8 hours, blood-brain barrier penetration with distribution to multiple brain regions, and predominantly urinary excretion with greater than 90 percent recovery in excreta within 72 hours. No human clinical trials have been conducted with BPAP as of the date of this monograph. The compound remains an investigational research tool with potential therapeutic relevance to neurodegenerative disease (Parkinson’s disease, Alzheimer’s disease), depression, and age-related cognitive decline. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.